{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:26:30Z","timestamp":1793330790525,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["li.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Laboratory Investigation"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.labinv.2026.106133","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T19:24:51Z","timestamp":1781205891000},"page":"106133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["FGFR3-Altered Urothelial Carcinoma: Clinicopathologic Observations With Emphasis on Variant Histology"],"prefix":"10.1016","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9603-6731","authenticated-orcid":false,"given":"Katrina","family":"Collins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.labinv.2026.106133_bib1","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/jnci\/djn175","article-title":"Evaluation of trends in the cost of initial cancer treatment","volume":"100","author":"Warren","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.labinv.2026.106133_bib2","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/j.labinv.2026.106133_bib3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1136\/jclinpath-2020-207115","article-title":"Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder","volume":"74","author":"Al-Obaidy","year":"2021","journal-title":"J Clin Pathol"},{"issue":"11","key":"10.1016\/j.labinv.2026.106133_bib4","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/ajhp\/zxac030","article-title":"Erdafitinib for locally advanced or metastatic urothelial carcinoma","volume":"79","author":"Siefker-Radtke","year":"2022","journal-title":"Am J Health Syst Pharm"},{"issue":"2","key":"10.1016\/j.labinv.2026.106133_bib5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.eururo.2025.09.4152","article-title":"Erdafitinib in patients with high- and intermediate-risk non-muscle-invasive bladder cancer: final analysis of THOR-2 study","volume":"89","author":"Daneshmand","year":"2026","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.labinv.2026.106133_bib6","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.eururo.2024.09.012","article-title":"FGFR inhibition in urothelial carcinoma","volume":"87","author":"Li","year":"2025","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.labinv.2026.106133_bib7","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0002-9440(10)64665-2","article-title":"Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors","volume":"158","author":"Billerey","year":"2001","journal-title":"Am J Pathol"},{"issue":"6","key":"10.1016\/j.labinv.2026.106133_bib8","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1158\/0008-5472.CAN-03-2421","article-title":"FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma","volume":"64","author":"van Rhijn","year":"2004","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.labinv.2026.106133_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0048993","article-title":"A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer","volume":"7","author":"Neuzillet","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.labinv.2026.106133_bib10","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41571-025-01095-x","article-title":"Towards biomarker-driven therapies for urothelial carcinoma","volume":"23","author":"Coca Membribes","year":"2026","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.labinv.2026.106133_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102530","article-title":"Role of FGFR3 in bladder cancer: treatment landscape and future challenges","volume":"115","author":"Ascione","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.labinv.2026.106133_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076743","article-title":"Advances in diagnosis and treatment of bladder cancer","volume":"384","author":"Lopez-Beltran","year":"2024","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.labinv.2026.106133_bib13","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ila2.70045","article-title":"Evolving landscape of precision medicine in bladder cancer: from challenges to clinical impact","volume":"3","author":"Ye","year":"2025","journal-title":"iLABMED"},{"issue":"22","key":"10.1016\/j.labinv.2026.106133_bib14","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1158\/1078-0432.CCR-23-1283","article-title":"Clinical and genomic landscape of FGFR3-altered urothelial carcinoma and treatment outcomes with erdafitinib: a real-world experience","volume":"29","author":"Guercio","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.labinv.2026.106133_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2025.04.005","article-title":"Clinical and genomic landscape of FGFR3 alterations across different stages of urothelial cancer","volume":"77","author":"Haas","year":"2025","journal-title":"Eur Urol Open Sci"},{"issue":"2","key":"10.1016\/j.labinv.2026.106133_bib16","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/PAP.0000000000000527","article-title":"Micropapillary urothelial carcinoma: a review and update","volume":"33","author":"Basar","year":"2026","journal-title":"Adv Anat Pathol"},{"issue":"5","key":"10.1016\/j.labinv.2026.106133_bib17","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.eururo.2025.04.008","article-title":"Clinical outcomes, genomic heterogeneity, and therapeutic considerations across histologic subtypes of urothelial carcinoma","volume":"88","author":"Chu","year":"2025","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.labinv.2026.106133_bib18","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/ajcp\/aqaf108","article-title":"Reflex somatic testing for the detection of FGFR alterations in urinary tract carcinomas: a dual-institutional experience","volume":"164","author":"Nguyen","year":"2025","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"10.1016\/j.labinv.2026.106133_bib19","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000544733","article-title":"Prognostic significance of programmed cell death-1, programmed cell death-ligand 1, programmed cell death-ligand 2, and fibroblast growth factor receptor 3 mRNA expression in bladder cancer","volume":"92","author":"Blanca","year":"2025","journal-title":"Pathobiology"},{"issue":"3","key":"10.1016\/j.labinv.2026.106133_bib20","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3390\/cancers18030444","article-title":"FGFR testing in metastatic urothelial carcinoma-who, when, and how to test","volume":"18","author":"Mansinho","year":"2026","journal-title":"Cancers (Basel)"}],"container-title":["Laboratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683726000632?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683726000632?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:13:46Z","timestamp":1790378026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0023683726000632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0023683726000632"],"URL":"https:\/\/doi.org\/10.1016\/j.labinv.2026.106133","relation":{},"ISSN":["0023-6837"],"issn-type":[{"value":"0023-6837","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FGFR3-Altered Urothelial Carcinoma: Clinicopathologic Observations With Emphasis on Variant Histology","name":"articletitle","label":"Article Title"},{"value":"Laboratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.labinv.2026.106133","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106133"}}